Tomislav Dragovich MD PhD
Gastrointestinal Cancer, Hematologic Oncology
Professor (Adj) of Medical Oncology, U. Of Texas MD Anderson Cancer Center; Division Chief, Hematology-Oncology and Director of Research, Banner MD Anderson Cancer Center, Arizona
Join to View Full Profile
1301 Palm Ave Ste 700Jacksonville, FL 32207
Phone+1 904-202-7300
Fax+1 904-202-2754
Dr. Dragovich is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 1997 - 2000
Louis A Weiss Memorial HospitalResidency, Internal Medicine, 1994 - 1997
University of Belgrade Faculty of MedicineClass of 1988
Certifications & Licensure
AZ State Medical License 2000 - 2026
FL State Medical License 2024 - 2026
IL State Medical License 1997 - 2002
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2002 Jun 01
- PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma Start of enrollment: 2005 Dec 01
- S9304A Study of Protein Expression in Tumor Tissue Samples From Patients With Stage II or Stage III Rectal Cancer Enrolled in Clinical Trial SWOG-9304 Start of enrollment: 2009 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 88 citationsAdjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resect...Charles S. Fuchs, Donna Niedzwiecki, Harvey J. Mamon, J. E. Tepper, Xing Ye
Journal of Clinical Oncology. 2017-10-04 - 769 citationsNanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, ...Andrea Wang-Gillam, Chung-Pin Li, György Bodoky, Andrew Dean, Yan Shen Shan
Lancet. 2016-02-06 - 21 citations90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapiesVincent J. Picozzi, Ramesh K. Ramanathan, Maeve A. Lowery, Allyson J. Ocean, Edith P. Mitchel
European Journal of Cancer. 2015-09-01
Press Mentions
Banner MD Anderson Launches Landmark Research ExpansionFebruary 11th, 2022
Grant Support
- Clinical Trials CoreNational Cancer Institute2007–2011
- Treatment Of Hypoxia Resistance In Pancreatic Cancer - ClinicalNational Cancer Institute2005–2009
- Core -- Clinical ResourcesNational Cancer Institute2002
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
